$Editorial: The safety and efficacy of ustekinumab in anti-TNFα refractory pediatric inflammatory bowel disease$

Editorial: The safety and efficacy of ustekinumab in anti-TNFα refractory pediatric inflammatory bowel disease

Saved in:

Bibliographic Details
Main Authors:	Katelynn K. Ho, David L. Suskind, Ghassan T. Wahbeh
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-03-01
Series:	The Saudi Journal of Gastroenterology
Online Access:	https://journals.lww.com/10.4103/sjg.sjg_384_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study
by: Abdulhamid Alhadab, et al.
Published: (2025-03-01)

Superior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study
by: Horng-Yih Chiu, et al.
Published: (2024-12-01)

Commentary: Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Yingjie Liu, et al.
Published: (2025-07-01)

Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease
by: María Calvo-Arbeloa, et al.
Published: (2020-03-01)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
by: Ignacio Marin-Jimenez, et al.
Published: (2020-12-01)

Correction: Inflammatory Bowel Disease: How Effective Is TNF-α Suppression?
by: PLOS ONE Staff
Published: (2017-01-01)

Efficacy of Dose Escalation of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
by: Mohammad Ebad Ur Rehman, et al.
Published: (2025-01-01)

Effectiveness and safety of TNF-α inhibitors and il-6 pathway antagonists for refractory Takayasu arteritis
by: V. E. Logina, et al.
Published: (2024-12-01)

Involvement of HLADQA1*05 in Patients with Inflammatory Bowel Disease Treated with Anti-TNF Drugs
by: Anna Pau, et al.
Published: (2025-01-01)

Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease Patients
by: Michelangelo Rottura, et al.
Published: (2025-03-01)

Favorable Effect of Anti-TNF Therapy on Insulin Sensitivity in Nonobese, Nondiabetic Patients with Inflammatory Bowel Disease
by: Stavroula A. Paschou, et al.
Published: (2018-01-01)

Ustekinumab Biosimilars
by: Elena Carmona-Rocha, et al.
Published: (2024-11-01)

Umbelliferone presents orofacial antinociceptive and anti-inflammatory activity via reduction of TNF-α in mice
by: P. N. S. Silva, et al.
Published: (2025-02-01)

TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
by: Romain Altwegg, et al.
Published: (2014-01-01)

Inflammatory linear verrucous epidermal nevus successfully treated with ustekinumab
by: Sara Almarzooqi, MD, et al.
Published: (2025-04-01)

IL-1/TNF-α Inflammatory and Anti-Inflammatory Synchronization Affects Gingival Stem/Progenitor Cells’ Regenerative Attributes
by: Fan Zhang, et al.
Published: (2017-01-01)

Cancer occurrence in patients with inflammatory bowel disease in treatment with anti-TNF: report of three cases and literature review
by: Lucas Camargo Gamba Martins do Amaral, et al.
Published: (2021-10-01)

EFFICACY OF ABATACEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS REFRACTORY TO TNF-α
by: Yu. M. Spivakovskii, et al.
Published: (2015-04-01)

PPAR-α Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice
by: Emanuela Esposito, et al.
Published: (2010-01-01)

Comparative Role of Anti-TNF Agents versus IL-12/23 Inhibitors in Inflammatory Bowel Disease: An Updated Review
by: Xue Bin Leong, et al.
Published: (2024-12-01)

Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01)

Case Report: Successful treatment of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and palmoplantar pustulosis with ustekinumab
by: Luxia Chen, et al.
Published: (2025-07-01)

Ulcerative Necrobiosis Lipoidica: Is There a Place for Anti-TNFα Treatment?
by: Rita Guedes, et al.
Published: (2012-01-01)

Anti-inflammatory effects of Andrographis paniculata (Fah Talai Jone) via TNFα-JNK pathway and bioactive compound identification
by: Praphat Manuelo Ruengthanoo, et al.
Published: (2025-02-01)

Vascular involvement in pediatric inflammatory bowel disease
by: Ezgi Kıran Taşcı, et al.
Published: (2023-03-01)

ORAL MANIFESTATIONS OF PEDIATRIC INFLAMMATORY BOWEL DISEASE
by: Diana-Claudia Lupu, et al.
Published: (2025-06-01)

OXIDATIVE STRESS AND INFLAMMATORY BOWEL DISEASE IN PEDIATRICS
by: M. Panayotova
Published: (2023-12-01)

Optimizing development of anti-TNFα biosimilars based on 10 years’ experience
by: Cecil Nick
Published: (2025-02-01)

Recurrent Pneumothorax in a Pediatric Patient with Crohn’s Disease Receiving Ustekinumab Treatment: Case Report
by: Marta Freixas Bermejo, et al.
Published: (2025-03-01)

Ustekinumab in the Treatment of Crohn’s Disease—A Narrative Review on Clinical Efficacy and Safety Profile
by: Dawid Piecuch, et al.
Published: (2025-05-01)

Immunological relationship between Helicobacter pylori and anti-tumor necrosis factor α agents in inflammatory bowel disease
by: Han Huang, et al.
Published: (2024-03-01)

Prediction of deep remission through serum TNF-α level at 1 year of treatment in pediatric Crohn’s disease
by: Seon Young Kim, et al.
Published: (2025-04-01)

Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases
by: Tao Yin, et al.
Published: (2025-12-01)

Special Considerations in Pediatric Inflammatory Bowel Disease Pathology
by: Alicia R. Andrews, et al.
Published: (2025-03-01)

Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database
by: Yanhong Deng, et al.
Published: (2025-08-01)

Anti-TNF-α antisense-oligonucleotide-conjugated PLG nanoparticles protect transplanted islets
by: Elizabeth J. Bealer, et al.
Published: (2025-06-01)

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment
by: Qianying Yu, et al.
Published: (2022-01-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Safety and efficacy of micropulse in pediatric eyes with refractory glaucoma
by: Raajaraajeshwari Sivasubramanian, et al.
Published: (2025-03-01)

Type 1 interferon signature and allograft inflammatory factor-1 contribute to refractoriness to TNF inhibition in ankylosing spondylitis
by: Woogil Song, et al.
Published: (2025-07-01)